United Nations E/CN.7/2001/3

# Economic and Social Council

Distr.: General
5 February 2001

Original: English

**Commission on Narcotic Drugs**
Forty-fourth session
Vienna, 20-29 March 2001
Item 5 (a) of the provisional agenda*
**Drug demand reduction: Action Plan for the Implementation of the Declaration on the Guiding Principles of Drug Demand Reduction**

## Revision of part II of the annual reports questionnaire

### Note by the Secretariat

1. In its resolution 43/1, entitled "Streamlining the annual reports questionnaire", the Commission on Narcotic Drugs decided to abolish sections 2 and 3 of part II of the annual reports questionnaire, since those sections duplicated the new biennial questionnaire for reporting on the action plans and measures adopted by the General Assembly at its twentieth special session.

2. In resolution 43/1, the Commission requested the Executive Director of the United Nations International Drug Control Programme to revise section 1 of part II of the annual reports questionnaire, and to test the resulting draft questionnaire in countries with various levels of development with regard to data-collection capacity.

3. The Commission also requested the Executive Director to use information technology, as part of the revision process, to assist countries with more efficient submission of the annual reports questionnaire on drug abuse, and to submit to the Commission on Narcotic Drugs at its forty-fourth session a draft of the revised annual reports questionnaire for examination with a view to introduction in 2002.

4. The draft of the revised part II of the annual reports questionnaire, entitled "Extent, patterns and trends of drug abuse", is annexed for the consideration of the Commission.

*E/CN.7/2001/1.

V.01-80642 (E) 120201 130201

LOGO

# Annual Reports Questionnaire

## Part II
## Drug Abuse

## Extent, patterns and trends of drug abuse

**Report of the Government of** _____

**Reporting Year** _____

Name, address, telephone, telex, fax and e-mail of the person responsible for national drug abuse data in the country.

**Name** _____

**Title/position** _____

**Address** _____

_____

**Telephone** _____ **Telex** _____

**Fax** _____ **E-mail** _____

Name, position, address, telephone, telex, fax and e-mail of the technical person responsible for the completion of Part II, *if different from above.*

**Name** _____

**Title/position** _____

**Address** _____

_____

**Telephone** _____ **Telex** _____

**Fax** _____ **E-mail** _____

The completed questionnaire should be addressed to:

**The Secretary-General**
**United Nations International Drug Control Programme**
**Vienna International Centre**
**PO Box 500**
**A-1400 Vienna, Austria**

## Structure of the questionnaire

This questionnaire contains the following sections:

1
**Prevalence of drug abuse among the general population**, *pages 1-4, questions Q1-Q9*

2
**Prevalence of drug abuse among the school (youth) population**, *pages 5-6, questions Q10-Q14*

3
**Injecting drug abuse**, *pages 7-8, questions Q15-Q22*

4
**Severe drug abuse**, *page 9, questions Q23-Q28*

5
**New developments in prevelence and patterns of drug abuse**, *pages 10-11, questions Q29-Q32*

6
**Drug-related morbidity**, *page 12, questions Q33-Q38* .

7
**Drug-related mortality**, *pages 13-14, questions Q39-Q47*

8
**Drug treatment**, *pages 15-16, questions Q48-Q58*

9
**Data collection capacity**, *page 17, questions Q59-Q61*

The sections ask for information at two distinguished levels, which recognises the fact that at present many countries do not yet have detailed data on these topics.

- **Summary expert opinions**
  The questions at this level ask for broad general 'qualitative' information. All questions refer to the past year, being the reporting period.The questions do not require actual data; if you have no data based on surveys, registers or formal estimation methods, the questions can be answered on the basis of the opinions of informed experts. *This should allow all countries to respond.*

- **Quantitative estimates**
  The questions at this level ask for quantitative statistical estimates. The ARQ includes standardized response categories – *the Global Standardized Data-set (GSD).* However, should your data not conform to these categories they can still be included. Please simply indicate the categories used (for example age-range, drug category) in the space provided.

  Estimates should be provided for the reporting year. Where this is not possible please include the most appropriate recent figures available. You should always specify the year of the estimate.

  If you do not have a national estimate you can specify an estimate for a part of the country or for a sub-population. If you have more than one of such partial estimates, you should take the estimate that in your opinion is the best alternative for a recent national estimate. In such case you should also specify the geographical or population coverage of the estimate as simply but explicit as possible, as well as the size of the reference population.

  For easy recognition a different background colour is used for quantitative estimates.

## General instructions for completion

- Many questions have pre-coded response categories and you only have to mark the appropriate boxes. Most other questions require to fill in rank order numbers, numbers or percentages.

- Several questions relate to drug classes or drug types. Whenever applicable, it is important that the information requested is reported for individual drugs. Although we have taken care to include all major drugs relevant for the topic concerned, the pre-coded lists might not fully suit the interests of your country. We therefore provide in each list the opportunity to add other drug classes or drug types. You may use these open categories also to insert alternative aggregate groups of drugs.
  *For example: some questions list 'heroin' and 'other opioids', if you only have information on all opioids, you should specify 'all opioids' as 'other drugs'.*

- In all tables you should leave cells blank if you do not know the answer or cannot provide the required figure. All empty cells will be interpreted as 'no information available'. If a figure would result in the value zero, please specify this as 0.

- Instructions for specific questions are provided in green boxes alongside the questions. In several places in the questionnaire we have provided open text boxes to add remarks and comments on the topic. For this purpose you can also use the empty pages at the end of the questionnaire.

- For further notes and definitions of technical terms used in this form please refer to the accompanying *'The ARQ, a Lexicon of Terms and Guidance Notes'.*

| Class of drugs / Type of drugs | Q1 Has there been significant use in the past year? NO | Q1 YES | Q2 How are main drug classes ranked in order of prevalence? Put in numerical order | Q3 Within each drug class separately, how are drug types ranked in order of prevalence? Put in numerical order |
|---|---|---|---|---|
| **Cannabis type** | ☐ | ☐ | ☐ | |
| Marihuana | ☐ | ☐ | | ☐ |
| Hashish | ☐ | ☐ | | ☐ |
| **Opioids** | ☐ | ☐ | ☐ | |
| Heroin | ☐ | ☐ | | ☐ |
| Opium | ☐ | ☐ | | ☐ |
| Other | ☐ | ☐ | | ☐ |
| **Cocaine type** | ☐ | ☐ | ☐ | |
| Powder (Salt) | ☐ | ☐ | | ☐ |
| Crack | ☐ | ☐ | | ☐ |
| Other | ☐ | ☐ | | ☐ |
| **Amphetamine type** | ☐ | ☐ | ☐ | |
| Amphetamine | ☐ | ☐ | | ☐ |
| Methamphetamine | ☐ | ☐ | | ☐ |
| 'Ecstasy' type | ☐ | ☐ | | ☐ |
| **Sedatives & Tranquillisers*** | ☐ | ☐ | ☐ | |
| Barbiturates | ☐ | ☐ | | ☐ |
| Benzodiazepines | ☐ | ☐ | | ☐ |
| **Hallucinogens** | ☐ | ☐ | ☐ | |
| LSD | ☐ | ☐ | | ☐ |
| Other | ☐ | ☐ | | ☐ |
| **Solvents & inhalants** | ☐ | ☐ | ☐ | |
| **Other drugs** | | | | |
| | ☐ | ☐ | ☐ | |
| | ☐ | ☐ | ☐ | |
| | ☐ | ☐ | ☐ | |

Complete Q2 and Q3 only when there has been significant use in the past year (Q1 = YES)

*Ranking of drugs:*
Start in Q2 with 1 for the most prevalent class of drugs, 2 for the second most prevalent class, etc. If necessary, you can assign equal rank numbers to more than one class of drug.
Continue with ranking individual drug types in Q3 in order of prevalence within each drug class separately.

*Non-prescribed / non-therapeutic use only

## Q4

**What has been the trend over the past year in prevalence of each drug class?**

## Q5

**What has been the trend over the past year in prevalence of each drug type?**

Complete Q4 and Q5 only when there has been significant use in the past year (Q1 = YES)

| Class of drugs / Type of drugs | Q4: Large increase | Q4: Some increase | Q4: No great change | Q4: Some decrease | Q4: Large decrease | Q5: Large increase | Q5: Some increase | Q5: No great change | Q5: Some decrease | Q5: Large decrease |
|---|---|---|---|---|---|---|---|---|---|---|
| **Cannabis type** | ☐ | ☐ | ☐ | ☐ | ☐ | | | | | |
| Marihuana | | | | | | ☐ | ☐ | ☐ | ☐ | ☐ |
| Hashish | | | | | | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Opioids** | ☐ | ☐ | ☐ | ☐ | ☐ | | | | | |
| Heroin | | | | | | ☐ | ☐ | ☐ | ☐ | ☐ |
| Opium | | | | | | ☐ | ☐ | ☐ | ☐ | ☐ |
| Other | | | | | | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Cocaine type** | ☐ | ☐ | ☐ | ☐ | ☐ | | | | | |
| Powder (Salt) | | | | | | ☐ | ☐ | ☐ | ☐ | ☐ |
| Crack | | | | | | ☐ | ☐ | ☐ | ☐ | ☐ |
| Other | | | | | | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Amphetamine type** | ☐ | ☐ | ☐ | ☐ | ☐ | | | | | |
| Amphetamine | | | | | | ☐ | ☐ | ☐ | ☐ | ☐ |
| Methamphetamine | | | | | | ☐ | ☐ | ☐ | ☐ | ☐ |
| 'Ecstasy' type | | | | | | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Sedatives & Tranquillisers*** | ☐ | ☐ | ☐ | ☐ | ☐ | | | | | |
| Barbiturates | | | | | | ☐ | ☐ | ☐ | ☐ | ☐ |
| Benzodiazepines | | | | | | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Hallucinogens** | ☐ | ☐ | ☐ | ☐ | ☐ | | | | | |
| LSD | | | | | | ☐ | ☐ | ☐ | ☐ | ☐ |
| Other | | | | | | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Solvents & inhalants** | ☐ | ☐ | ☐ | ☐ | ☐ | | | | | |
| **Other drugs** | | | | | | | | | | |
| | ☐ | ☐ | ☐ | ☐ | ☐ | | | | | |
| | ☐ | ☐ | ☐ | ☐ | ☐ | | | | | |
| | ☐ | ☐ | ☐ | ☐ | ☐ | | | | | |

*Non-prescribed / non-therapeutic use only

## Q6

**Do you have an estimate of drug prevalence among the general population?**

Tick ONLY ONE

- ☐ **No** → Proceed to Q10
- ☐ **Yes** an estimate for the country as a whole
- ☐ **Yes** an estimate for a part of the country or a sub-population

## Q7

**For which year does the estimate apply?**
**Which part of the country or the population is covered by the estimate?**

**Year of the national estimate** ☐☐☐☐

**Year of the partial estimate** ☐☐☐☐

**Part of the country or sub-population for which the estimate applies**

**Estimated size of the reference population for which the estimate applies** ☐☐☐☐☐☐☐☐

| Please complete questions Q8 – Q9 for the estimate specified in Q7 above | Q8 What is the estimated LIFETIME prevalence rate per 100 among the general population? *Specify separately for the female population* | | Q9 What is the estimated prevalence rate per 100 among the general population in the REPORTING YEAR? *Specify separately for the female population* | |
|---|---|---|---|---|
| **Preferred prevalence measure** | | | **Last 12 months** | |
| Prevalence measure used | | | | |
| **Preferred age range** | **15-64 years** | | **15-64 years** | |
| Age range used | | | | |
| | All % | Females % | All % | Females % |
| **Cannabis type** | | | | |
| **Opioids** | | | | |
| Heroin | | | | |
| Opium | | | | |
| Other | | | | |
| **Cocaine type** | | | | |
| Powder (Salt) | | | | |
| Crack | | | | |
| Other | | | | |
| **Amphetamine type** | | | | |
| Amphetamine | | | | |
| Methamphetamine | | | | |
| 'Ecstasy' type | | | | |
| **Sedatives & Tranquillisers*** | | | | |
| Barbiturates | | | | |
| Benzodiazepines | | | | |
| **Hallucinogens** | | | | |
| LSD | | | | |
| Other | | | | |
| **Solvents & inhalants** | | | | |
| **Other drugs** | | | | |
| | | | | |
| | | | | |
| | | | | |

All figures should be rates per 100 of population. You do not need to add % after your figures.

Provide decimal figures. If an estimate results in a zero prevalence rate please note as 0.

If you have an estimate of the NUMBERS of users, please convert these into rates per 100 of the reference population.

If you do not have figures for the preferred age range, you should specify the age ranges that applies to your estimates.

If you do not have figures for the preferred prevalence measure for the reporting year, you should specify the prevalence measure used for your estimate.

*Non-prescribed / non-therapeutic use only

## Q10

**Do you have an estimate of drug prevalence among the school (youth) population?**

Tick ONLY ONE

☐ **No** → Proceed to Q15

☐ **Yes**
an estimate for the country as a whole

☐ **Yes**
an estimate for a part of the country or a sub-population

## Q11

**For which year does the estimate apply?**
**Which Part of the country or sub-population is covered by the estimate?**

**Year of the national estimate** ☐

**Year of the partial estimate** ☐

**Part of the country or sub-population for which the estimate applies**

☐

**Estimated size of the reference population for which the estimate applies** ☐

Please complete questions Q12 – Q14 for the estimate specified in Q10

| | Q12 | Q13 | Q14 |
|---|---|---|---|
| | **What is the estimated prevalence rate per 100 among YOUNG ADOLESCENTS population in the REPORTING YEAR?** ***Specify separately for the female population*** | **What is the estimated LIFETIME prevalence rate per 100 among the school (youth) population?** ***Specify separately for the female population*** | **What is the estimated prevalence rate per 100 among the school (youth) population in the REPORTING YEAR?** ***Specify separately for the female population*** |
| **Preferred prevalence measure** | **Last 12 months** | | **Last 12 months** |
| Prevalence measure used | | | |
| **Preferred age range** | **15-16 years** | | |
| Age range used | | | |
| | All % / Females % | All % / Females % | All % / Females % |
| **Cannabis type** | | | |
| **Opioids** | | | |
| Heroin | | | |
| Opium | | | |
| Other | | | |
| **Cocaine type** | | | |
| Powder (Salt) | | | |
| Crack | | | |
| Other | | | |
| **Amphetamine type** | | | |
| Amphetamine | | | |
| Methamphetamine | | | |
| 'Ecstasy' type | | | |
| **Sedatives & Tranquillisers*** | | | |
| Barbiturates | | | |
| Benzodiazepines | | | |
| **Hallucinogens** | | | |
| LSD | | | |
| Other | | | |
| **Solvents & inhalants** | | | |
| **Other drugs** | | | |
| | | | |
| | | | |
| | | | |

All figures should be rates per 100 of population.
You do not need to add % after your figures.

Provide decimal figures. If an estimate results in a zero prevalence rate please note as 0.

If you have an estimate of the NUMBERS of users, please convert these into rates per 100 of the reference population.

You should always specify the age ranges used for the estimates.

If you do not have figures for the preferred age range of young adolescents, you should specify the age range that applies to your estimates.

If you do not have figures for the preferred prevalence measure for the reporting year, you should specify the prevalence measure used for your estimate.

*Non-prescribed / non-therapeutic use only

## Q15

**Has there been significant practice of injecting among drug users in the past year?**

## Q16

**What has been the trend in injecting over the past year?**

If there has been no significant practice of injecting (All drugs = NO), proceed to Q22.

| | NO | YES | Large increase | Some increase | No great change | Some decrease | Large decrease |
|---|---|---|---|---|---|---|---|
| **All drugs** (not differentiated) | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Heroin** | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Other opioids** | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Cocaine type** | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Amphetamine** | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Methamphetamine** | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| **'Ecstasy' type** | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Other drugs** | | | | | | | |
| _____ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| _____ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| _____ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |

With 'sharing' needles or syringes we mean 'using a needle or syringe that has been used previously by someone else'.

## Q17

**Has there been significant practice of sharing needles or syringes among drug injectors in the past year?**

☐ **No** → Proceed to Q19

☐ **Yes**

## Q18

**What has been the trend over the past year in sharing needles or syringes among drug injectors?**

| Large increase | Some increase | No great change | Some decrease | Large decrease |
|---|---|---|---|---|
| ☐ | ☐ | ☐ | ☐ | ☐ |

## Q19

**Do you have an estimate of the percentage of drug injectors among drug users?**

Tick ONLY ONE

☐ **No** → Proceed to Q23

☐ **Yes**
an estimate for the country as a whole

☐ **Yes**
an estimate for a part of the country or a subgroup of drug users

## Q20

**For which year does the estimate apply? Which part of the country or subgroup of drug users is covered by the estimate?**

**Year of the national estimate** ☐

**Year of the partial estimate** ☐

**Part of the country or subgroup of drug users for which the estimate applies**

☐

**Estimated size of the reference population for which the estimate applies** ☐

Please complete question Q21 for the estimate specified in Q20

## Q21

**What is the estimated PERCENTAGE of drug injectors among all drug users?**

If there has been no significant practice of sharing (Q17=NO), proceed to Q23

## Q22

**What is the estimated PERCENTAGE of drug injectors that have shared needles or syringes in the past year?**

| | Q21 | Q22 |
|---|---|---|
| **All drugs** (not differentiated) | ☐ | ☐ |
| **Heroin** | ☐ | |
| **Other opioids** | ☐ | |
| **Cocaine type** | ☐ | |
| **Amphetamine** | ☐ | |
| **Methamphetamine** | ☐ | |
| **'Ecstasy' type** | ☐ | |
| **Other drugs** | | |
| ☐ | ☐ | |
| ☐ | ☐ | |
| ☐ | ☐ | |

## Q23

**Does your country make a distinction between drug users in general and drug users who are considered particularly problematic, chronic or in need of help?**

☐ **No** → Proceed to Q29

☐ **Yes**

## Q24

**What has been the trend over the past year in "severe / problematic" drug use?**

| Large increase | Some increase | No great change | Some decrease | Large decrease |
|---|---|---|---|---|
| ☐ | ☐ | ☐ | ☐ | ☐ |



## Q25

**Do you have an estimate of drug users, who are considered particularly problematic, chronic users or in need of help?**

Tick ONLY ONE

☐ **No** → Proceed to Q29

☐ **Yes**
an estimate for the country as a whole

☐ **Yes**
an estimate for a part of the country or a subgroup of drug users

## Q26

**For which year does the estimate apply?**
**Which part of the country or which subgroup of drug users is covered by the estimate?**

**Year of the national estimate** ☐

**Year of the partial estimate** ☐

**Part of the country or subgroup of drug users for which the estimate applies**

☐

**Estimated size of the reference population for which the estimate applies** ☐

Please complete questions Q27 – Q28 for the estimate specified in Q26

## Q27

**What is the estimated number of "severe / problematic" drug users?**

☐

## Q28

**Which definition of "severe / problematic users" applies to the estimated number of Q27 and how is the estimate calculated?**

☐

## Q29

**Have new drugs or new patterns of drug use been reported in the past year?**

☐ No → Proceed to Q31

☐ Yes

## Q30

**Which new drugs or new patterns of use have been reported?**

## Q31

**Have new groups of drug users been reported in the past year?**

☐ No → Proceed to Q33

☐ Yes

## Q32

**Which new groups of drug users have been reported and in relation to which types of drugs?**

**Please use the space below to document any other developments in prevalence and patterns of drug abuse in your country over the past year.**

## Q33

**Have there been reports about prevalence of infections among drug injectors in the past year?**

## Q34

**What has been the trend over the past year in prevalence of infections among drug injectors?**

| | NO | YES | Large increase | Some increase | No great change | Some decrease | Large decrease |
|---|---|---|---|---|---|---|---|
| Hepatitis B | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| Hepatitis C | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| HIV | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |



## Q35

**Do you have an estimate of drug users having any of the infections mentioned in the table above?**

Tick ONLY ONE

☐ **No** → Proceed to Q39

☐ **Yes**
an estimate for the country as a whole

☐ **Yes**
an estimate for a part of the country or a subgroup of drug injectors

## Q36

**For which year does the estimate apply?**
**Which part of the country or which subgroup of drug injectors is covered by the estimate?**

**Year of the national estimate** ☐

**Year of the partial estimate** ☐

**Part of the country or subgroup of drug injectors for which the estimate applies**

☐

**Estimated size of the reference population for which the estimate applies** ☐

Please complete questions Q37 – Q38 for the estimate specified in Q36

## Q37

**What is the estimated NUMBER of infected drug injectors?**

## Q38

**What is the estimated PERCENTAGE of infected persons among drug injectors?**

| | Q37 | Q38 |
|---|---|---|
| Hepatitis B | ☐ | ☐ |
| Hepatitis C | ☐ | ☐ |
| HIV | ☐ | ☐ |

| | Q39 Have there been reports about drug-related deaths in the past year? | | Q40 How are drugs ranked in order of the primary cause in drug-related deaths? | Q41 What has been the trend over the past year in drug-related deaths? | | | | |
|---|---|---|---|---|---|---|---|---|
| | NO | YES | Put in numerical order | Large increase | Some increase | No great change | Some decrease | Large decrease |
| **All drugs** (not differentiated) | ☐ | ☐ | | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Heroin** | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Other opioids** | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Cocaine type** | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Amphetamine** | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Methamphetamine** | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| **'Ecstasy' type** | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Other drugs** | | | | | | | | |
| ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |

*Ranking of drugs as primary cause in drug-related deaths:*
Start with 1 for the drug most frequently the primary cause in drug-related deaths, 2 for the second most frequent primary cause, etc. If necessary, you may assign equal rank numbers to more than one drug.

## Q42

**Do you have an estimate of the number of drug-related deaths?**

Tick ONLY ONE

☐ **No** → Proceed to Q48

☐ **Yes**
an estimate for the country as a whole

☐ **Yes**
an estimate for a part of the country or a sub-population

## Q43

**For which year does the estimate apply? Which part of the country or sub-population is covered by the estimate?**

**Year of the national estimate** ☐

**Year of the partial estimate** ☐

**Part of the country or sub-population for which the estimate applies**

☐

**Estimated size of the reference population for which the estimate applies** ☐

| Please complete questions Q44 – Q47 for the estimate specified in Q43 | Q44 What is the estimated TOTAL number of drug-related deaths? | Q45 What is the estimated number of FATAL DRUG OVERDOSES ONLY? | Q46 What is the estimated number of Drug-related AIDS DEATHS? | Q47 What is the estimated number of drug-related OTHER DEATHS (excluding fatal drug overdoses and AIDS deaths)? |
|---|---|---|---|---|
| **All drugs** (not differentiated) | ☐ | ☐ | ☐ | ☐ |
| **Heroin** | ☐ | ☐ | ☐ | ☐ |
| **Other opioids** | ☐ | ☐ | ☐ | ☐ |
| **Cocaine type** | ☐ | ☐ | ☐ | ☐ |
| **Amphetamine** | ☐ | ☐ | ☐ | ☐ |
| **Methamphetamine** | ☐ | ☐ | ☐ | ☐ |
| **'Ecstasy' type** | ☐ | ☐ | ☐ | ☐ |
| **Other drugs** | | | | |
| ☐ | ☐ | ☐ | ☐ | ☐ |
| ☐ | ☐ | ☐ | ☐ | ☐ |
| ☐ | ☐ | ☐ | ☐ | ☐ |

## Q48

**Have people received treatment for drug problems in the past year?**

## Q49

**How are drugs ranked in order of the primary cause of receiving treatment?**

## Q50

**What has been the trend over the past year in the numbers of people receiving treatment?**

*Ranking of drugs as primary cause of treatment:*
Start with 1 for the drug most frequently the primary cause of treatment, 2 for the second most frequent primary cause, etc. If necessary, you may assign equal rank numbers to more than one drug.

| | NO | YES | Put in numerical order | Large increase | Some increase | No great change | Some decrease | Large decrease |
|---|---|---|---|---|---|---|---|---|
| **All drugs** (not differentiated) | ☐ | ☐ | | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Cannabis type** | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Heroin** | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Other opioids** | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Cocaine type** | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Amphetamine** | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Methamphetamine** | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| **'Ecstasy' type** | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Other drugs** | | | | | | | | |
| ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |
| ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |



## Q51

**Do you have an estimate of the number of people receiving treatment for drug problems?**

Tick ONLY ONE

☐ **No** → Proceed to Q25

☐ **Yes**
an estimate for the country as a whole

☐ **Yes**
an estimate for a part of the country or a selection of treatment facilities

## Q52

**For which year does the estimate apply?**
**Which part of the country or selection of treatment facilities is covered by the estimate?**

**Year of the national estimate** ☐

**Year of the partial estimate** ☐

**Part of the country for which the estimate applies**

**Types of treatment facilities included and/or excluded in the estimate**

Please complete questions Q53 – Q58 for the estimate specified in Q52

| | Q53 What is the estimated NUMBER of people receiving treatment for drug problems? | Q54 What is the estimated PERCENTAGE of people receiving treatment for the FIRST TIME EVER among people in treatment? | Q55 What is the estimated PERCENTAGE of FEMALES among people in treatment | Q56 What is the estimated MEAN AGE of people in treatment? | Q57 What is the estimated PERCENTAGE of DRUG INJECTORS among people in treatment? |
|---|---|---|---|---|---|
| **All drugs** (not differentiated) | | | | | |
| **Cannabis type** | | | | | |
| **Heroin** | | | | | |
| **Other opioids** | | | | | |
| **Cocaine type** | | | | | |
| **Amphetamine** | | | | | |
| **Methamphetamine** | | | | | |
| **'Ecstasy' type** | | | | | |
| **Other drugs** | | | | | |
| | | | | | |
| | | | | | |

## Q58

**Which definition of "people treated for drug problems" applies to the figures in the columns of Q53 – Q57 above?**

| | Tick as Appropriate | Tick as Appropriate | Tick as Appropriate | Tick as Appropriate | Tick as Appropriate |
|---|---|---|---|---|---|
| **People starting treatment during the year** | ☐ | ☐ | ☐ | ☐ | ☐ |
| **People receiving treatment during the year** | ☐ | ☐ | ☐ | ☐ | ☐ |
| **People in treatment at census date in the year** | ☐ | ☐ | ☐ | ☐ | ☐ |
| **People discharged from treatment during the year** | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Other** | ☐ | ☐ | ☐ | ☐ | ☐ |

## Q59

**Has your country capacity with regard to data collection instruments specified below?**

## Q60

**How would you qualify the present suitability of these instruments for making national estimates about the drug situation?**

| | Q59 NO | Q59 YES | Q60 Poor | Q60 Moderate | Q60 Good |
|---|---|---|---|---|---|
| **Registers** | | | | | |
| Specialised treatment register | ☐ | ☐ | ☐ | ☐ | ☐ |
| Registers on drug-related morbidity | ☐ | ☐ | ☐ | ☐ | ☐ |
| Registers on drug-related mortality | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Survey instruments** | | | | | |
| Prevalence surveys among the general population | ☐ | ☐ | ☐ | ☐ | ☐ |
| Prevalence surveys among school populations | ☐ | ☐ | ☐ | ☐ | ☐ |
| Surveys among drug users | ☐ | ☐ | ☐ | ☐ | ☐ |
| **Qualitative research instruments** | | | | | |
| Rapid Situation Assessment | ☐ | ☐ | ☐ | ☐ | ☐ |
| Other ☐ | ☐ | ☐ | ☐ | ☐ | ☐ |

## Q61

**If applicable, what are the main obstacles for implementation or improvement of data collection instruments suitable for making national estimates about the drug situation?**

## Reports

**Please list below relevant national reports or major studies about the extent, patterns or trends in drug abuse in your country, published in the past year.** ***Specify author, title and year of publication. Attach copies of documents and reports if possible.***

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

## Additional information

**Please use the space below to add notes of clarification to any of the information contained in this questionnaire or to document any issue that you wish to draw to the attention of UNDCP.**